Sign up
Pharma Capital

VolitionRx continuing to make strong progress with another 'very, very good quarter'

Cameron Reynolds, president and chief executive of VolitionRx Limited (NYSE MKT:VNRX), discusses with Proactive the firm's second quarter update as well as recent company highlights.

 

View full VNRX profile

VolitionRx Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.